TABLE 2.
Subgroup analysis of the effect of OM3-FA monotherapy on lipid profile.
| Serum lipids | Subgroup type | Group | Study (n) | Sample (n) | Effect estimate | P-value | I 2 | Pheterogeneity |
| TG | Dosage | <4 g | 11 | 1122 | −40.74 [−68.40, −13.08] | 0.004 | 97% | <0.00001 |
| ≥4 g | 8 | 12490 | −35.03 [−46.26, −23.80] | <0.00001 | 78% | <0.0001 | ||
| type | EPA | 5 | 411 | −41.19 [−62.70, −19.69] | 0.0002 | 85% | <0.0001 | |
| DHA | 3 | 88 | −31.91 [−50.84, −12.98] | 0.001 | 0% | 0.41 | ||
| EPA+DHA | 12 | 13113 | −39.17 [−60.95, −17.39] | 0.0004 | 98% | <0.00001 | ||
| Baseline TG level (mg/dl) | <200 | 4 | 262 | −27.54 [−37.53, −17.54] | <0.00001 | 1% | 0.40 | |
| ≥200, <500 | 11 | 12398 | −48.26 [−75.02, −21.51] | 0.0004 | 98% | <0.00001 | ||
| ≥500 | 4 | 952 | −26.43 [−37.12, −15.75] | <0.00001 | 63% | 0.05 | ||
| Duration (Week) | <12 | 11 | 767 | −47.22 [−74.56, −19.88] | 0.0007 | 96% | <0.00001 | |
| ≥12 | 8 | 12845 | −26.56 [−34.99, −18.13] | <0.00001 | 73% | 0.0005 | ||
| TC | Dosage | <4 g | 9 | 585 | −0.67 [−5.01, 3.66] | 0.76 | 49% | 0.05 |
| ≥4 g | 7 | 12433 | −4.72 [−8.70, −0.73] | 0.02 | 72% | 0.0007 | ||
| type | EPA | 5 | 411 | −2.71 [−10.45, 5.03] | 0.49 | 77% | 0.002 | |
| DHA | 2 | 71 | 14.78 [4.61, 24.95] | 0.004 | 0% | 0.82 | ||
| EPA+DHA | 10 | 12536 | −4.55 [−6.95, −2.15] | <0.0002 | 36% | 0.12 | ||
| Baseline TG level (mg/dl) | <200 | 4 | 262 | 2.97 [−5.91, 11.86] | 0.51 | 63% | 0.03 | |
| ≥200, <500 | 9 | 12324 | −2.31 [−4.99, 0.38] | 0.09 | 48% | 0.05 | ||
| ≥500 | 3 | 432 | −10.01 [−15.52, −4.50] | 0.0004 | 51% | 0.13 | ||
| Duration (Week) | <12 | 10 | 750 | −1.57 [−5.25, 2.11] | 0.40 | 47% | 0.04 | |
| ≥12 | 6 | 12268 | −4.27 [−9.65, 1.10] | 0.12 | 79% | 0.0003 | ||
| HDL-C | Dosage | <4 g | 11 | 1122 | 2.01 [−0.94, 4.96] | 0.18 | 67% | 0.0008 |
| ≥4 g | 7 | 12433 | 1.32 [−0.37, 3.01] | 0.12 | 35% | 0.15 | ||
| type | EPA | 5 | 411 | 3.64 [−3.01, 10.28] | 0.28 | 85% | <0.00001 | |
| DHA | 3 | 88 | 3.59 [−0.53, 7.71] | 0.09 | 32% | 0.23 | ||
| EPA+DHA | 11 | 13056 | 1.22 [0.70, 1.73] | <0.00001 | 0% | 0.73 | ||
| Baseline TG level (mg/dl) | <200 | 4 | 262 | 2.94 [0.67, 5.21] | 0.01 | 0% | 0.46 | |
| ≥200, <500 | 10 | 12341 | 1.16 [0.64, 1.68] | <0.00001 | 0% | 0.71 | ||
| ≥500 | 4 | 952 | 5.21 [−3.76, 14.18] | 0.25 | 87% | <0.0001 | ||
| Duration (Week) | <12 | 11 | 767 | 0.53 [−0.83, 1.90] | 0.44 | 0% | 0.46 | |
| ≥12 | 7 | 12788 | 3.75 [−0.42, 7.92] | 0.08 | 79% | <0.0001 | ||
| LDL-C | Dosage | <4 g | 11 | 1122 | 13.46 [3.65, 23.26] | 0.007 | 81% | <0.00001 |
| ≥4 g | 8 | 12490 | 6.67 [1.31, 12.04] | 0.01 | 58% | 0.01 | ||
| type | EPA | 5 | 411 | 24.05 [3.84, 44.26] | 0.02 | 91% | <0.00001 | |
| DHA | 3 | 88 | 16.91 [8.76, 25.06] | <0.0001 | 0% | 0.96 | ||
| EPA+DHA | 12 | 13113 | 4.39 [0.22, 8.55] | 0.04 | 40% | 0.07 | ||
| Baseline TG level (mg/dl) | <200 | 4 | 262 | 3.81 [−4.80, 12.42] | 0.39 | 38% | 0.16 | |
| ≥200, <500 | 11 | 12398 | 9.86 [3.25, 16.48] | 0.003 | 81% | <0.00001 | ||
| ≥500 | 14 | 952 | 13.42 [0.05, 26.79] | 0.05 | 71% | 0.01 | ||
| Duration (Week) | <12 | 11 | 767 | 9.31 [1.27, 17.34] | 0.02 | 78% | <0.00001 | |
| ≥12 | 8 | 12845 | 10.09 [2.54, 17.65] | 0.009 | 71% | 0.001 | ||
| VLDL-C | Dosage | <4 g | 2 | 604 | −23.00 [−50.94, 4.94] | 0.11 | 85% | 0.009 |
| ≥4 g | 2 | 348 | −26.40 [−35.72, −17.09] | <0.00001 | 0% | 0.45 | ||
| type | EPA | 2 | 235 | −35.84 [−48.49, −23.18] | <0.00001 | 0% | 0.74 | |
| DHA | 0 | – | – | – | – | – | ||
| EPA+DHA | 2 | 717 | −17.46 [−32.50, −2.43] | 0.02 | 67% | 0.08 | ||
| Baseline TG level (mg/dl) | <200 | 0 | – | – | – | – | – | |
| ≥200, <500 | 0 | – | – | – | – | – | ||
| ≥500 | 4 | 952 | −25.12 [−37.09, −13.14] | <0.0001 | 62% | 0.05 | ||
| Duration (Week) | <12 | 0 | – | – | – | – | – | |
| ≥12 | 4 | 952 | −25.12 [−37.09, −13.14] | <0.0001 | 62% | 0.05 | ||
| Non-HDL-C | Dosage | <4 g | 5 | 822 | −2.85 [−7.63, 1.93] | 0.24 | 62% | 0.03 |
| ≥4 g | 6 | 12357 | −7.32 [−10.67, −3.96] | <0.0001 | 55% | 0.05 | ||
| type | EPA | 3 | 337 | −5.93 [−16.20, 4.35] | 0.26 | 86% | 0.0009 | |
| DHA | 1 | 17 | 4.30 [−5.78, 14.38] | 0.40 | – | – | ||
| EPA+DHA | 7 | 12825 | −5.41 [−6.56, −4.25] | <0.00001 | 4% | 0.39 | ||
| Baseline TG level (mg/dl) | <200 | 1 | 26 | −11.99 [−24.97, 0.99] | 0.07 | – | – | |
| ≥200, <500 | 6 | 12201 | −3.04 [−6.26, 0.18] | 0.06 | 64% | 0.02 | ||
| ≥500 | 4 | 952 | −9.39 [−13.84, −4.94] | < 0.0001 | 39% | 0.18 | ||
| Duration (Week) | <12 | 6 | 499 | −2.92 [−7.20, 1.36] | 0.18 | 55% | 0.05 | |
| ≥12 | 5 | 12680 | −7.83 [−11.48, −4.18] | <0.0001 | 59% | 0.04 | ||
| Apo-B | Dosage | <4 g | 6 | 375 | −4.11 [−10.44, 2.21] | 0.20 | 37% | 0.16 |
| ≥4 g | 5 | 12188 | −2.02 [−5.65, 1.61] | 0.28 | 48% | 0.11 | ||
| type | EPA | 3 | 270 | −5.93 [−16.20, 4.35] | 0.41 | 61% | 0.08 | |
| DHA | 0 | – | – | – | – | – | ||
| EPA+DHA | 8 | 12293 | −5.41 [−6.56, −4.25] | 0.26 | 26% | 0.22 | ||
| Baseline TG level (mg/dl) | <200 | 2 | 112 | −3.63 [−17.16, 9.91] | 0.60 | 0% | 0.74 | |
| ≥200, <500 | 6 | 12019 | −3.55 [−7.84, 0.74] | 0.10 | 40% | 0.14 | ||
| ≥500 | 3 | 432 | −1.01 [−8.31, 6.30] | 0.79 | 73% | 0.02 | ||
| Duration (Week) | <12 | 7 | 403 | −5.19 [−9.70, −0.69] | 0.02 | 0% | 0.58 | |
| ≥12 | 4 | 12160 | −0.86 [−4.80, 3.07] | 0.67 | 61% | 0.05 | ||
| Apo-AI | Dosage | <4 g | 6 | 375 | 1.79 [−2.76, 6.33] | 0.44 | 31% | 0.20 |
| ≥4 g | 3 | 309 | −3.20 [−8.79, 2.39] | 0.26 | 72% | 0.03 | ||
| type | EPA | 2 | 119 | 4.62 [−0.08, 9.31] | 0.05 | 0% | 0.56 | |
| DHA | 0 | – | – | – | – | – | ||
| EPA+DHA | 7 | 565 | −2.30 [−6.10, 1.49] | 0.23 | 49% | 0.06 | ||
| Baseline TG level (mg/dl) | <200 | 2 | 112 | 4.72 [−2.90, 12.34] | 0.23 | 0% | 0.60 | |
| ≥200, <500 | 5 | 291 | −1.40 [−5.98, 3.18] | 0.55 | 39% | 0.16 | ||
| ≥500 | 2 | 281 | −1.40 [−12.18, 9.37] | 0.80 | 92% | 0.0006 | ||
| Duration (Week) | <12 | 7 | 403 | −0.14 [−4.49, 4.21] | 0.95 | 40% | 0.12 | |
| ≥12 | 2 | 281 | −1.40 [−12.18, 9.37] | 0.80 | 92% | 0.0006 |